Scandinavian ChemoTech AB Class B (CMOTEC.B) AI Stock Analysis

• Market Cap: €144.73M
• Dividend Yield: N/A
• Average Volume (3M): 98.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.49
• Revenue Growth: 113.59%
• EPS Growth: 54.12%
• Country: SE
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 21,692,312
• 10 Day Avg. Volume: 118,161
• 30 Day Avg. Volume: 98,369
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: ―

Scandinavian ChemoTech AB shows strong revenue growth and has a solid financial structure with no debt, reducing financial risk. However, persistent operational inefficiencies and ongoing cash burn weigh on profitability and valuation. Technical indicators point to short-term momentum, but potential overbought conditions warrant caution. Overall, while there are promising aspects, significant challenges in achieving sustainable profitability remain.

Scandinavian ChemoTech AB Class B Business Overview & Revenue Model

Company Description

Scandinavian ChemoTech AB Class B (CMOTEC.B) is a Swedish medical technology company that operates within the healthcare sector, focusing on developing innovative treatments for cancer. The company specializes in the research, development, and commercialization of tumor-specific electroporation techniques aimed at improving the effectiveness of cancer treatment. With a commitment to enhancing patient outcomes, Scandinavian ChemoTech provides advanced medical solutions that leverage cutting-edge technology to address unmet needs in oncology care.

How the Company Makes Money

Scandinavian ChemoTech AB generates revenue primarily through the sale and licensing of its proprietary medical technologies and devices designed for cancer treatment. The company's revenue streams include direct sales of its electroporation equipment to healthcare providers and hospitals, as well as potential licensing agreements with other medical technology companies. Additionally, Scandinavian ChemoTech may engage in strategic partnerships or collaborations that contribute to its earnings, leveraging its specialized expertise in electroporation to expand its market reach and enhance its product offerings. These revenue-generating activities are supported by ongoing research and development investments, aimed at continuously improving the efficacy and safety of their treatments.

Scandinavian ChemoTech AB Class B Financial Statement Overview

Summary

Scandinavian ChemoTech AB shows promising revenue growth but continues to face challenges with profitability and cash flow management. The company's financial structure benefits from a lack of debt, reducing financial risk, but operational improvements are needed to achieve sustainable profitability. Continued investment and strategic adjustments may be required to address ongoing losses and cash outflows.

Income Statement

The company demonstrates significant revenue growth, with a sharp increase from SEK 473,000 in 2022 to SEK 6,566,000 in 2024. However, the company has consistently reported negative net income, resulting in negative net profit margins, indicating ongoing losses. Gross profit margins have improved, but the EBIT and EBITDA margins remain negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet shows an improvement in the equity ratio, as stockholders' equity remains positive and there is no debt on the balance sheet as of 2024. The return on equity is negative due to persistent losses, but the absence of debt reduces financial risk. The company has a reasonable buffer of cash and short-term investments relative to its liabilities.

Cash Flow

The company's free cash flow has improved from highly negative figures in previous years but remains negative, indicating ongoing cash burn. Operating cash flows have been negative, but financing activities have provided necessary liquidity. The cash flow to net income ratios are negative due to the negative net income and operating cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.69M	6.57M	2.82M	473.00K	49.00K	131.00K
Gross Profit	-3.64M	4.78M	1.66M	-55.00K	323.00K	-14.00K
EBITDA	-10.51M	-12.38M	-19.58M	-20.81M	-17.03M	-10.77M
Net Income	-13.84M	-13.72M	-21.09M	-24.58M	-18.42M	-12.50M
Balance Sheet
Total Assets	13.07M	13.38M	14.87M	21.70M	25.81M	15.99M
Cash, Cash Equivalents and Short-Term Investments	1.02M	949.00K	923.00K	5.85M	8.68M	1.49M
Total Debt	0.00	0.00	0.00	0.00	53.00K	2.71M
Total Liabilities	9.37M	7.40M	3.84M	7.71M	1.89M	6.75M
Stockholders Equity	3.70M	5.98M	11.03M	13.99M	23.92M	9.24M
Cash Flow
Free Cash Flow	-9.53M	-13.19M	-18.91M	-19.96M	-22.36M	-10.32M
Operating Cash Flow	-9.53M	-13.14M	-18.23M	-19.63M	-19.18M	-8.49M
Investing Cash Flow	35.00K	-2.00K	-468.00K	-603.00K	-3.33M	-1.83M
Financing Cash Flow	8.86M	13.17M	13.77M	17.26M	29.71M	8.98M

Scandinavian ChemoTech AB Class B Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CMOTEC.B, the sentiment is Positive. The current price of 6.7 is above the 20-day moving average (MA) of 4.03, above the 50-day MA of 3.14, and above the 200-day MA of 1.93, indicating a bullish trend. The MACD of 0.71 indicates Negative momentum. The RSI at 83.74 is Negative, neither overbought nor oversold. The STOCH value of 93.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CMOTEC.B.

Scandinavian ChemoTech AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMOTEC.B	54 Neutral	€144.73M	―	-380.40%	―	113.59%	54.12%
STABL	34 Underperform	17.63M	-1.37	0.00%	―	0.00%	68.74%
QUIA	32 Underperform	8.07M	-0.66	0.00%	―	-100.00%	50.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%